Baylor College spinout AlloVir has filed to raise up to $100m in an offering that will support the clinical development of a treatment for viral diseases.

AlloVir, a US-based cell therapy developer based on research at Baylor College Of Medicine, filed for a $100m initial public offering on the Nasdaq Global Market on Monday.
Founded in 2013, AlloVir is working on cell therapies generated from healthy donors that are designed to restore natural immunity in patients who suffer from T cell deficiencies and are at risk from potentially fatal viral diseases.
The company was set up by ElevateBio, a holding firm established to…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in